Modular Medical EPS MODD
Diluted earnings per share by quarter and over the last twelve months, from 2010.
- Last 12 months, to Jun 30, 2026
- −$10.63
- Latest quarter, Q1 FY27
- −$1.19
- Fiscal year 2026
- −$13.14
Modular Medical's earnings per share was −$10.63 over the twelve months to Jun 30, 2026.
In its latest quarter, Q1 FY27, it was −$1.19.
Earnings per share over time
Fiscal year by fiscal year
| Fiscal year | EPS | Change |
|---|---|---|
| FY2026 | −$13.14 | n/a |
| FY2025 | −$15.30 | n/a |
| FY2024 | −$24.00 | n/a |
| FY2023 | −$37.50 | n/a |
| FY2022 | −$83.10 | n/a |
| FY2021 | −$35.40 | n/a |
| FY2020 | −$26.10 | n/a |
| FY2019 | −$13.50 | n/a |
| FY2018 | −$3.96 | n/a |
| FY2017 | −$1.44 | n/a |
| FY2016 | −$3.60 | n/a |
| FY2015 | −$3.60 | n/a |
| FY2014 | −$2.70 | n/a |
| FY2013 | −$2.70 | n/a |
| FY2012 | −$2.70 | n/a |
Each fiscal year is the twelve months to its fourth quarter.
Quarter by quarter
| Quarter | Ended | EPS | On a year earlier | Last 12 months |
|---|---|---|---|---|
| Q1 FY27 | −$1.19 | n/a | −$10.63 | |
| Q4 FY26 | −$1.94 | n/a | −$13.14 | |
| Q3 FY26 | −$3.30 | n/a | −$14.80 | |
| Q2 FY26 | −$4.20 | n/a | −$15.40 | |
| Q1 FY26 | −$3.70 | n/a | −$15.40 | |
| Q4 FY25 | −$3.60 | n/a | −$15.30 | |
| Q3 FY25 | −$3.90 | n/a | −$16.50 | |
| Q2 FY25 | −$4.20 | n/a | −$19.50 | |
| Q1 FY25 | −$3.60 | n/a | −$21.00 | |
| Q4 FY24 | −$4.80 | n/a | −$24.00 | |
| Q3 FY24 | −$6.90 | n/a | −$27.90 | |
| Q2 FY24 | −$5.70 | n/a | −$30.30 |
Against its peers
Companies in Medical - Instruments & Supplies nearest Modular Medical's size, closest first, today.
| Company | EPS, 12 months | Growth |
|---|---|---|
| MODDModular Medical | −$10.63 | |
| NEPHNephros | $0.16 | +33% a year |
| APTAlpha Pro Tech | $0.41 | +24% a year |
| KEQUKewaunee Scientific | $2.76 | −33% a year |
| Peer median | $0.41 |
What the EPS figure tells you
Net income divided by diluted shares. The denominator of PE.
One-off charges and gains swing it. The TTM view smooths a single odd quarter.
More on Modular Medical
Valuation data, not investment advice. Prices as of . Reported figures come from the company's filings with the SEC.